Mizuho Maintains Outperform on Insmed, Raises Price Target to $206

Mizuho analyst Graig Suvannavejh has maintained an 'Outperform' rating on Insmed (NASDAQ: INSM) and raised the price target from $204 to $206. This adjustment reflects a positive outlook on the company's performance.